Therefore, investigating genetic variants in the SLC34A2 gene, especially within the MX35 epitope region, in patients with malignant neoplasms is critical for identifying alterations that impact the recognition of the MX35 epitope by monoclonal antibodies. Here, SLC34A2 is linked to cancer.